Expeditors International of Washington Free cash flow increased by 9.7% to $296.62M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 10.0%, from $329.47M to $296.62M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 3.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $23.76M | $167.50M | $293.55M | $399.53M | $520.49M | $654.46M | $468.37M | $536.29M | $147.97M | $181.99M | $147.64M | $246.72M | $118.83M | $77.68M | $239.67M | $329.47M | $163.34M | $190.27M | $270.32M | $296.62M |
| QoQ Change | — | +605.0% | +75.3% | +36.1% | +30.3% | +25.7% | -28.4% | +14.5% | -72.4% | +23.0% | -18.9% | +67.1% | -51.8% | -34.6% | +208.5% | +37.5% | -50.4% | +16.5% | +42.1% | +9.7% |
| YoY Change | — | — | — | — | >999% | +290.7% | +59.6% | +34.2% | -71.6% | -72.2% | -68.5% | -54.0% | -19.7% | -57.3% | +62.3% | +33.5% | +37.5% | +144.9% | +12.8% | -10.0% |